The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a huge mover today! The stock decreased 5.11% or $2 during the last trading session, hitting $37.15. About 438,621 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 145.15% since April 27, 2016 and is uptrending. It has outperformed by 139.92% the S&P500.
The move comes after 7 months negative chart setup for the $1.23B company. It was reported on Nov, 30 by Barchart.com. We have $34.18 PT which if reached, will make NASDAQ:AERI worth $98.40M less.
Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on March, 7. They expect $-0.68 EPS, up 10.53% or $0.08 from last year’s $-0.76 per share. After $-0.81 actual EPS reported by Aerie Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -16.05% EPS growth.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 10 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 10 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 20 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Thursday, September 15 the stock rating was maintained by Needham with “Buy”. RBC Capital Markets maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Thursday, September 15. RBC Capital Markets has “Outperform” rating and $55 price target. The firm earned “Buy” rating on Thursday, September 15 by Stifel Nicolaus. The stock has “Outperform” rating given by RBC Capital Markets on Wednesday, November 4. As per Friday, October 28, the company rating was maintained by RBC Capital Markets. Aegis Capital initiated Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Tuesday, November 1 with “Buy” rating. On Thursday, September 17 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The company was maintained on Thursday, September 15 by Cantor Fitzgerald. The stock has “Buy” rating given by Cantor Fitzgerald on Friday, August 7. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, September 17.
According to Zacks Investment Research, “Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 2.49 in 2016 Q2. Its up 0.82, from 1.67 in 2016Q1. The ratio is positive, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Waddell & Reed Fin Incorporated owns 187,700 shares or 0.01% of their US portfolio. Essex Inv holds 107,700 shares or 0.32% of its portfolio. Moreover, California State Teachers Retirement Systems has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 50,502 shares. Jpmorgan Chase & holds 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 284 shares. Colony Grp Incorporated Ltd Com last reported 11,870 shares in the company. Moreover, Parametric Port Associates Lc has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 46,994 shares. Vanguard Inc last reported 1.01 million shares in the company. Adage Capital Grp Incorporated Limited Liability Corporation holds 2.10 million shares or 0.1% of its portfolio. Rice Hall James And Assoc Limited has 158,932 shares for 0.16% of their US portfolio. Blackrock Gru has 7,724 shares for 0% of their US portfolio. Schwab Charles Investment Mgmt last reported 37,544 shares in the company. Baker Bros Advsr L P accumulated 0.06% or 299,356 shares. Nationwide Fund Advisors, a Pennsylvania-based fund reported 79,473 shares. Geode Cap Management Limited Com reported 185,594 shares or 0% of all its holdings. Raymond James Assoc has 52,563 shares for 0% of their US portfolio.
Insider Transactions: Since July 22, 2016, the stock had 1 insider purchase, and 0 insider sales for $4.38 million net activity. Another trade for 250,000 shares valued at $4.38M was made by Foresite Capital Management II – LLC on Friday, July 22.
Another recent and important Aerie Pharmaceuticals Inc (NASDAQ:AERI) news was published by Fool.com which published an article titled: “Why Aerie Pharmaceuticals Is Soaring 54% Today” on September 15, 2016.
AERI Company Profile
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.